Practice
Medical cannabinoids
Scott A. McLeod and Jean-François Lemay
CMAJ July 31, 2017 189 (30) E995; DOI: https://doi.org/10.1503/cmaj.161395
Scott A. McLeod
Department of Pediatrics (McLeod, Lemay), Cumming School of Medicine, University of Calgary, Alberta Children’s Hospital, Calgary, Alta.
MDJean-François Lemay
Department of Pediatrics (McLeod, Lemay), Cumming School of Medicine, University of Calgary, Alberta Children’s Hospital, Calgary, Alta.
MDIn this issue
Article tools
Respond to this article
Medical cannabinoids
Scott A. McLeod, Jean-François Lemay
CMAJ Jul 2017, 189 (30) E995; DOI: 10.1503/cmaj.161395
Jump to section
- Article
- The principal cannabinoids, cannabidiol and tetrahydrocannabinol, have different medical effects
- Despite widespread availability, medical cannabinoids are still experimental
- Cannabinoids can increase the risk of motor vehicle collisions4
- Cannabinoids should be titrated slowly with low initial dosing
- Users of medical cannabinoids may be vulnerable to psychosis
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis
- Simplified guideline for prescribing medical cannabinoids in primary care
- Lignes directrices simplifiees en matiere de prescription de cannabinoides medicaux en soins de premiere ligne
- Medical cannabinoids